NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Pancreatic Cancer Resectable

Interventions

DEVICE

ctDNA-based MRD detection

Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit

Trial Locations (1)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai